Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): An open-label, multicentre, phase 2, randomised controlled trial

The Lancet Oncology

Volumn 15, Issue 11, 2014, Pages 1245-1253

  Hong, Yong Sang ^a   Nam, Byung Ho ^b   Kim, Kyu pyo ^a   Kim, Jeong Eun ^a   Park, Seong Joon ^a   Park, Young Suk ^c   Park, Joon Oh ^c   Kim, Sun Young ^b   Kim, Tae You ^d   Kim, Jee Hyun ^e   Ahn, Joong Bae ^f   Lim, Seok Byung ^a   Yu, Chang Sik ^a   Kim, Jin Cheon ^a   Yun, Seong Hyeon ^c   Kim, Jong Hoon ^a   Park, Jin hong ^a   Park, Hee Chul ^c   Jung, Kyung Hae ^a   Kim, Tae Won ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; UFT; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM ANTERIOR RESECTION; RECTUM CANCER; RECTUM SURGERY; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; TOTAL MESORECTAL EXCISION; VOMITING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PREOPERATIVE CARE; PROCEDURES; PROGNOSIS; RECTAL NEOPLASMS; SURVIVAL; TAIWAN; TREATMENT OUTCOME; TUMOR INVASION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PREOPERATIVE CARE; PROGNOSIS; RECTAL NEOPLASMS; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME;

EID: 84908142852     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70377-8     Document Type: Article

References (34)

1. Siegel R, Desantis C, Jemal A Colorectal cancer statistics, 2014. CA Cancer J Clin 2014, 64:104-117.
2. Martling A, Cedermark B, Johansson H, Rutqvist LE, Holm T The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. Br J Surg 2002, 89:1008-1013.
3. van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011, 12:575-582. for the Dutch Colorectal Cancer Group.
4. Roh MS, Colangelo LH, O'Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009, 27:5124-5130.
5. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012, 30:1926-1933.
6. Kim TH, Chang HJ, Kim DY, et al. Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Int J Radiat Oncol Biol Phys 2010, 77:1158-1165.
7. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005, 23:8688-8696.
8. Bujko K, Glynne-Jones R, Bujko M Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol 2010, 21:1743-1750.
9. Khrizman P, Niland JC, ter Veer A, et al. Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. J Clin Oncol 2013, 31:30-38.
10. Tiselius C, Gunnarsson U, Smedh K, Glimelius B, Pahlman L Patients with rectal cancer receiving adjuvant chemotherapy have an increased survival: a population-based longitudinal study. Ann Oncol 2013, 24:160-165.
11. van de Velde CJ, Boelens PG, Borras JM, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer 2014, 50:e1-34.
12. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370:2020-2029. QUASAR Collaborative Group.
13. Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011, 29:3768-3774.
14. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27:3109-3116.
15. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
16. Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007, 25:102-109.
17. Yun YH, Park YS, Lee ES, et al. Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res 2004, 13:863-868.
18. Sprangers MAG, te Velde A, Aaronson NK The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). Eur J Cancer 1999, 35:238-247. on behalf of the European Organization for Research and Treatment of Cancer Study Group on Quality of Life.
19. Collette L, Bosset JF, den Dulk M, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007, 25:4379-4386.
20. Petersen SH, Harling H, Kirkeby LT, Wille-Jorgensen P, Mocellin S Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012, 3. CD004078.
21. Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014, 15:184-190. for the EORTC Radiation Oncology Group.
22. Breugom AJ, van den Broek CBM, van Gijn W, et al. The value of adjuvant chemotherapy in rectal cancer patients after preoperative radiotherapy or chemoradiation followed by TME-surgery: the PROCTOR/SCRIPT study. Eur J Cancer 2013, 49(suppl 3):S1.
23. Glynne-Jones R, Counsell N, Quirke P, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 2014, 25:1356-1362.
24. Glimelius B, Tiret E, Cervantes A, Arnold D Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013, 24(suppl 6):vi81-vi88. on behalf of the ESMO Guidelines Working Group.
25. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355:1114-1123.
26. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24:4620-4625.
27. Hofheinz R-D, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012, 13:579-588.
28. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011, 29:2773-2780.
29. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012, 30:4558-4565.
30. O'Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2014, 32:1927-1934.
31. Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012, 13:679-687. on behalf of the German Rectal Cancer Study Group.
32. Rödel C, Liersch T, Fietkau R, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: results of the German CAO/ARO/AIO-04 randomized phase III trial. ASCO Annual Meeting 2014; Chicago, IL, USA; May 30-June 3, 2014. Abstr 3500.
33. Schmoll H-J, Haustermans K, Price TJ, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: disease-free survival results at interim analysis. ASCO Annual Meeting 2014; Chicago, IL, USA; May 30-June 3, 2014. Abstr 3501.
34. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.